Allspring Global Investments Holdings LLC Boosts Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Allspring Global Investments Holdings LLC boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIVFree Report) by 1,207.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,410 shares of the company’s stock after acquiring an additional 65,025 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Roivant Sciences were worth $742,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ROIV. Citigroup Inc. grew its stake in shares of Roivant Sciences by 45.6% in the 3rd quarter. Citigroup Inc. now owns 326,431 shares of the company’s stock worth $3,813,000 after buying an additional 102,279 shares in the last quarter. Morgan Stanley grew its stake in shares of Roivant Sciences by 48.7% in the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock worth $225,560,000 after buying an additional 6,324,915 shares in the last quarter. Beryl Capital Management LLC purchased a new position in shares of Roivant Sciences in the 4th quarter worth $2,808,000. First Turn Management LLC purchased a new position in shares of Roivant Sciences in the 4th quarter worth $15,312,000. Finally, Decheng Capital LLC purchased a new position in shares of Roivant Sciences in the 4th quarter worth $14,371,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Up 0.7 %

ROIV stock opened at $10.72 on Tuesday. The firm has a market cap of $7.92 billion, a PE ratio of 2.12 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a quick ratio of 25.24 and a current ratio of 25.24. The firm’s fifty day moving average is $10.90 and its 200 day moving average is $10.88. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its quarterly earnings results on Thursday, May 30th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $28.93 million for the quarter, compared to analyst estimates of $32.46 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. On average, research analysts forecast that Roivant Sciences Ltd. will post -1.12 EPS for the current year.

Analysts Set New Price Targets

ROIV has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, June 18th. The Goldman Sachs Group lifted their price target on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Friday, May 31st. Truist Financial reaffirmed a “buy” rating and set a $23.00 price target on shares of Roivant Sciences in a research note on Monday, March 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.90.

Read Our Latest Research Report on Roivant Sciences

Roivant Sciences Profile

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Recommended Stories

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.